If you’ve been following our articles on reader reports about the Daytrana ADHD patch, you’ll know that reader experiences vary widely. With over 170 comments about the methylphenidate transdermal patch, it’s time for another follow-up — and some additional resources for those experiencing problems with the patch.
Evidence that potential blockbuster weight loss drug Acomplia (rimonabant) causes neurological and psychiatric problems and increases the risk of suicide has led to a unanimous vote against the drug by a US FDA advisory panel. Although rimonabant is already being marketed in 37 countries, it is now unlikely the FDA will approve the weight loss drug, to have been sold in the United States under the name ‘Zimulti’, without more positive data on safety.
If you’ve searched our database of clinical trials research exploring drug safety and efficacy, you’ll know the search facility can quickly zero in on relevant drug research. But what if you’d just like to browse through trials by condition or by sponsor, or just find out about trials with a particular status?
Parents continue to experience problems removing the backing of the new Daytrana patch for ADHD, according to user feedback collected at CounsellingResource.com. Nonetheless, we’ve received three times as many reports of positive overall experiences as reports of negative experiences with Daytrana. Our users have also contributed several suggestions about removing the Daytrana patch adhesive from the skin, and many questions about using the medication. For example, is it OK to cut the patches in half or thirds?
Not enough is known about the potential dangers associated with antidepressant medications, according to the UK’s Mental Health Foundation. The group has responded to the controversy about the GlaxoSmithKline Seroxat case covered in an expose by the Panorama programme.
We comply with the HONcode standard for trustworthy health information: verify here.
